Goldman Sachs’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $339K | Sell |
152,847
-17,610
| -10% | -$31.5K | ﹤0.01% | 5831 |
|
|
2025
Q4 | $278K | Buy |
170,457
+141,940
| +498% | +$219K | ﹤0.01% | 5903 |
|
|
2025
Q3 | $37.1K | Sell |
28,517
-255,307
| -90% | -$221K | ﹤0.01% | 6200 |
|
|
2025
Q2 | $93.6K | Buy |
283,824
+179,389
| +172% | +$54K | ﹤0.01% | 5827 |
|
|
2025
Q1 | $32.6K | Sell |
104,435
-93,688
| -47% | -$57.6K | ﹤0.01% | 5920 |
|
|
2024
Q4 | $185K | Buy |
198,123
+67,844
| +52% | +$75.9K | ﹤0.01% | 5664 |
|
|
2024
Q3 | $154K | Buy |
130,279
+3,453
| +3% | +$3.61K | ﹤0.01% | 5514 |
|
|
2024
Q2 | $97.6K | Buy |
126,826
+67,842
| +115% | +$189K | ﹤0.01% | 5407 |
|
|
2024
Q1 | $180K | Sell |
58,984
-2,811
| -5% | -$9.41K | ﹤0.01% | 5143 |
|
|
2023
Q4 | $199K | Buy |
61,795
+5,039
| +9% | +$17.2K | ﹤0.01% | 5156 |
|
|
2023
Q3 | $218K | Sell |
56,756
-9,366
| -14% | -$33.7K | ﹤0.01% | 5015 |
|
|
2023
Q2 | $217K | Buy |
66,122
+54,948
| +492% | +$187K | ﹤0.01% | 5150 |
|
|
2023
Q1 | $28.8K | Sell |
11,174
-3,981
| -26% | -$9.43K | ﹤0.01% | 5627 |
|
|
2022
Q4 | $28.2K | Sell |
15,155
-20,919
| -58% | -$35.6K | ﹤0.01% | 5666 |
|
|
2022
Q3 | $67K | Sell |
36,074
-7,527
| -17% | -$15.7K | ﹤0.01% | 5764 |
|
|
2022
Q2 | $94K | Sell |
43,601
-1,746
| -4% | -$4.22K | ﹤0.01% | 5882 |
|
|
2022
Q1 | $143K | Sell |
45,347
-4,042
| -8% | -$12.7K | ﹤0.01% | 5989 |
|
|
2021
Q4 | $158K | Sell |
49,389
-48,156
| -49% | -$165K | ﹤0.01% | 5989 |
|
|
2021
Q3 | $328K | Sell |
97,545
-16,027
| -14% | -$58.4K | ﹤0.01% | 5442 |
|
|
2021
Q2 | $444K | Sell |
113,572
-637,993
| -85% | -$2.52M | ﹤0.01% | 5292 |
|
|
2021
Q1 | $3.02M | Buy |
751,565
+277,020
| +58% | +$920K | ﹤0.01% | 3581 |
|
|
2020
Q4 | $1.1M | Buy |
474,545
+423,032
| +821% | +$1.97M | ﹤0.01% | 4138 |
|
|
2020
Q3 | $296K | Sell |
51,513
-63,161
| -55% | -$423K | ﹤0.01% | 4746 |
|
|
2020
Q2 | $845K | Sell |
114,674
-21,577
| -16% | -$101K | ﹤0.01% | 4071 |
|
|
2020
Q1 | $406K | Buy |
136,251
+50,739
| +59% | +$171K | ﹤0.01% | 4334 |
|
|
2019
Q4 | $355K | Buy |
85,512
+49,580
| +138% | +$157K | ﹤0.01% | 4682 |
|
|
2019
Q3 | $116K | Sell |
35,932
-10,797
| -23% | -$24.5K | ﹤0.01% | 4943 |
|
|
2019
Q2 | $87K | Buy |
46,729
+23,210
| +99% | +$41.5K | ﹤0.01% | 4948 |
|
|
2019
Q1 | $42K | Buy |
23,519
+7,889
| +50% | +$19.7K | ﹤0.01% | 5015 |
|
|
2018
Q4 | $38K | Sell |
15,630
-11,329
| -42% | -$51.7K | ﹤0.01% | 5114 |
|
|
2018
Q3 | $153K | Buy |
+26,959
| New | +$204K | ﹤0.01% | 4996 |
|
|
2018
Q2 | – | Sell |
-14,866
| Closed | -$105K | – | 5904 |
|
|
2018
Q1 | $105K | Buy |
+14,866
| New | +$120K | ﹤0.01% | 5268 |
|
|
2017
Q3 | – | Sell |
-87,943
| Closed | -$923K | – | 6794 |
|
|
2017
Q2 | $923K | Buy |
+87,943
| New | +$1.15M | ﹤0.01% | 4542 |
|
Other funds holding OVID
RCM
AAA
EAM
VCM
ACM
SVCM
Goldman Sachs's OVID Position: Q1 2026 in Review
Goldman Sachs reduced its Ovid Therapeutics (OVID) stake by 10% in Q1 2026, selling an estimated $31.5K and leaving 152,847 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #5831.
Goldman Sachs first reported a position in OVID in Q2 2017 and has held it in 33 quarters since. The position peaked at $3.02M in Q1 2021. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.
- Goldman Sachs held 152,847 shares of Ovid Therapeutics worth $339K as of Q1 2026.
- Goldman Sachs sold 17,610 Ovid Therapeutics shares in Q1 2026, an estimated $31.5K.
- Ovid Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5831 holding.
- Goldman Sachs first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 33 quarters since.
- Goldman Sachs's Ovid Therapeutics position peaked at $3.02M in Q1 2021.
- 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.